IPO observation Haisen Pharmaceutical's heavy single product supervision risk is high and low R&D investment may be difficult to support the road of transformation.

  • Post date April 15, 2022 — 11:18 Post Lock Login to View

Key Data Concepts:   
? These are the company names, stock quotes, topics, and entities related to this data.

000739 300702 300713 ADD Industry Apeloa Pharmaceutical China Shipbuilding Industry Group Power Citic Securities Fujian Funeng Ningbo Menovo Pharmaceutical Shenzhenrease Technology Xinjiang Sayram Modern Agriculture Zhejiang Ausun Pharmaceutical Zhejiang Tianyu Pharmaceutical Science, Technology Accounting, Audit Restructuring, Recapitalisation Strategy, Marketing Annual, Special Corporate Meeting Annual Report Research, Development Health, Beauty Product Pharmaceutical Construction, Property Renovation Energy, Resource Market, Exchange Air Pollution, Pollution Workplace Health, Safety Food, Drink Enthusiasm House, Home Food, Drink Regulations History Technology, Engineering Athletics, Track, Field Series Economy, Business, Finance Environment Health

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets


Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!


Already have an account?
Login



Related Data